Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Universitaet Muenster |
| Country | Germany |
| Start Date | Oct 01, 2022 |
| End Date | Sep 30, 2027 |
| Duration | 1,825 days |
| Number of Grantees | 29 |
| Roles | Coordinator; Participant; Third Party; Associated Partner |
| Data Source | European Commission |
| Grant ID | 101057454 |
A key problem in Mental Health is that up to one third of patients suffering from major mental disorders develop resistance against drug therapy.
However, patients showing early signs of treatment resistance (TR) do not receive adequate early intensive pharmacological treatment but instead they undergo a stepwise trial-and-error treatment approach.
This situation originates from three major knowledge and translation gaps: i.) we lack effective methods to identify individuals at risk for TR early in the disease process, ii.) we lack effective, personalized treatment strategies grounded in insights into the biological basis of TR, and iii.) we lack efficient processes to translate scientific insights about TR into clinical practice, primary care and treatment guidelines.
It is the central goal of PSYCH-STRATA to bridge these gaps and pave the way for a shift towards a treatment decision-making process tailored for the individual at risk for TR.
To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for TR across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression.
PSYCH-STRATA will i.) dissect the biological basis of TR and establish criteria to enable early detection of individuals at risk for TR based on the integrated analysis of an unprecedented collection of genetic, biological, digital mental health, and clinical data. ii.) Moreover, we will determine effective treatment strategies of individuals at risk for TR early in the treatment process, based on pan-European clinical trials in SCZ, BD and MDD.
These efforts will enable the establishment of novel multimodal machine learning models to predict TR risk and treatment response.
Lastly, iii.) we will enable the translation of these findings into clinical practice by prototyping the integration of personalized treatment decision support and patient-oriented decision-making mental health boards.
Universitaet Muenster; Region Hovedstaden; Ludwig-Maximilians-Universitaet Muenchen; Global Alliance of Mental Illness Advocacy Networks Europe Aisbl; Novamechanics Monoprosopi Ike; Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev; European Research Services Gmbh; Klinikum Der Ludwig-Maximilians-Universitat Munchen; Oslo Universitetssykehus Hf; Universita Degli Studi Di Cagliari; Institut Du Cerveau Et de la Moelle Epiniere; World Psychiatric Association; Fundacion Para la Investigacion Biomedica Del Hospital Gregorio Maranon; Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer; Universitair Medisch Centrum Utrecht; Karlsruher Institut Fuer Technologie; Charite - Universitaetsmedizin Berlin; Universitetet I Oslo; Alma Mater Studiorum - Universita Di Bologna; The University of Adelaide; Hospital Clinic de Barcelona; Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev; Katholieke Universiteit Leuven; Fundacio Centre de Regulacio Genomica; Goeteborgs Universitet; Universita Degli Studi Di Brescia; King's College London; Cardiff University; Kairos Gmbh
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant